



---

---

---

---

**TABLE OF CONTENTS**

**PART I. FINANCIAL INFORMATION**

_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____
_____	_____	_____

**PART II. OTHER INFORMATION**

_____	_____	_____
_____	_____	_____
_____	_____	_____

---





---

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

*The accompanying unaudited Notes to Condensed Consolidated Financial Statements are an integral part of these statements.*

---



---

---



---

**OPKO Health, Inc. and Subsidiaries**  
**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)**

---

















---

*Impairment of long-lived assets.*

*Income taxes.*

---



---

*Pending accounting pronouncements*

---





**NOTE 6 INVESTMENTS**

*Investments*

A table with four rows. The first row is a solid light blue bar. The second row has a black diagonal slash from the top-left to the bottom-right. The third row is a solid light blue bar. The fourth row has a black diagonal slash from the top-left to the bottom-right. The table is partially obscured by large black letters 'BY' and 'Q'.

*Equity method investments*

---

*Warrants and options*

*Investments in variable interest entities*

---



**NOTE 7 DEBT**

	<hr/>	<hr/>
	<hr/>	<hr/>
	<hr/>	<hr/>
	<hr/>	<hr/>
	<hr/>	<hr/>







---

---

---

---

\_\_\_\_\_

_____	_____	_____	_____	_____
_____	_____	_____	_____	_____

**NOTE 9 FAIR VALUE MEASUREMENTS**

_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____

_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____
_____	_____	_____	_____	_____

\_\_\_\_\_

---

---

---

---

---

**NOTE 10 DERIVATIVE CONTRACTS R 1 R**

---

---

---





---

*Client Payors.*

*Patients.*

---



---

---

<i>Royaldee</i>
<i>Royaldee</i>
<i>Royaldee</i>

*Revenue from intellectual property and other*

---

---

---



---

*Vifor Fresenius Medical Care Renal Pharma Ltd*

*Rayaldee*

*Rayaldee*  
*Rayaldee*

---

---


---

---





---



---











---


*Revenue*

---









---

**Other**

*Interest income*

*Interest expense*

*Fair value changes of derivative instruments, net*

*Other income (expense), net*

*Income tax benefit (provision)*

*Loss from investments in investees*

**FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2021 AND 2020**

---

---

---

---

---

---

---







*Research and development expenses*

**Research and Development Expenses**








---

---

---

*Royaldee*

---



---


---



---

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

---



---

---

**PART II. OTHER INFORMATION**

**Item 1. Legal Proceedings**

---

---

**Item 1A. Risk Factors**

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

**Item 3. Defaults Upon Senior Securities**

**Item 4. Mine Safety Disclosures**

**Item 5. Use of Proceeds**

---

\_\_\_\_\_

\_\_\_\_\_

---

**SIGNATURES**

**OPKO Health, Inc.**

---

## **CERTIFICATIONS**

**CERTIFICATIONS**

---

**Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**  
**(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)**

---



c